Marion Bertrand
Saint-denis-de-palin, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
First- and Second-Year Outcomes After Nirsevimab Immunization.
Journal: JAMA pediatrics
Published: August 10, 2026
Dual Immunization Against RSV With RSVpreF and Nirsevimab.
Journal: JAMA pediatrics
Published: May 18, 2026
Prevention of Respiratory Syncytial Virus-Related Hospitalization in Newborns-Reply.
Journal: JAMA
Published: April 09, 2026
Maternal RSVpreF Immunisation Against Infant RSV Hospitalisation: Nationwide Population-Based Effectiveness and Durability Study.
Journal: The Lancet regional health. Europe
Published: March 17, 2026
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
Journal: JAMA
Published: December 22, 2025
COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France.
COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France.
Journal: JAMA network open
Published: December 04, 2025
Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.
Journal: Therapie
Published: December 02, 2025
Social and Regional Inequalities in Maternal Respiratory Syncytial Virus Vaccination in France.
Journal: JAMA network open
Published: September 23, 2025
Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy: Analysis From the 2024-2025 Immunization Campaign in France.
Journal: Obstetrics and gynecology
Published: August 18, 2025
Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization study.
Journal: JAC-antimicrobial resistance
Published: May 19, 2025
Sociodemographic Characteristics of Infants Receiving Nirsevimab.
Journal: JAMA network open
Published: April 09, 2025
Last Updated: 09/26/2026